secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2026-05-12T21:00:09+00:00
Accession:  0001213900-26-055164
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada reports Q1 2026 net loss of $19.1M; NDV-01 Phase 2 shows 95% CR rate; cash $234M through 2029
--------------------------------------------------------------------------------

- NDV-01 12-month Phase 2 in high-risk NMIBC: 95% CR at any time, 76% durable CR; BCG-unresponsive: 94% CR, 80% durable.
- Cash balance $234.0M as of March 31, 2026, expected to fund operations through 2029 after $160M PIPE in March.
- Net loss $19.1M ($0.22/share) vs $17.6M ($0.58) Q1 2025; R&D expense $8.1M; G&A $11.4M.
- Phase 3 RESCUE registrational program on track for mid-2026; provisional patent filed April 2026 with term to 2047.
- Upcoming milestones: IND filing mid-2026, initial Phase 3 data by YE 2026, Sepranolone Phase 2 in Prader-Willi mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390026055164/0001213900-26-055164-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390026055164/ea0290414-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-055164

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer